SUSTAIN-6 Trial

SUSTAIN-6 was designed as a non-inferiority trial to assess the CV safety of semaglutide versus placebo. 1 The trial included >3000 patients with T2D who had established CV disease or were aged ≥60 years with ≥1 CV risk factor.1 This module details the CV endpoints and safety results from the trial.

SUSTAIN-6 Trial
Rate this content
  • SUSTAIN-6 Trial
  • SUSTAIN-6: study design
  • SUSTAIN-6: baseline characteristics (1/2)
  • SUSTAIN-6: baseline characteristics (2/2)
  • SUSTAIN-6: renal function at baseline
Do you want to go to the Presentation Builder section to create a new presentation?
Cancel Go